ライフサイエンスコーパス: ventilator-associated pneumonia

1 outcome that was not targeted by the policy (ventilator-associated pneumonia).

2 n the intensive care unit was complicated by ventilator-associated pneumonia.

3 in the intensive-care unit and incidence of ventilator-associated pneumonia.

4 more related to other medical features than ventilator-associated pneumonia.

5 ould be a promising therapeutic strategy for ventilator-associated pneumonia.

6 obials or as monotherapy in the treatment of ventilator-associated pneumonia.

7 ematological parameters supporting suspected ventilator-associated pneumonia.

8 imary role of gravity in the pathogenesis of ventilator-associated pneumonia.

9 ssociated condition constructs for detecting ventilator-associated pneumonia.

10 oportion of standardized cases classified as ventilator-associated pneumonia.

11 f oropharyngeal pathogens and development of ventilator-associated pneumonia.

12 Primary endpoint was the rate of ventilator-associated pneumonia.

13 t demonstrate older age as a risk factor for ventilator-associated pneumonia.

14 s has been implicated in the pathogenesis of ventilator-associated pneumonia.

15 l care strategies involving toothbrushing on ventilator-associated pneumonia.

16 with or without toothbrushing, and examined ventilator-associated pneumonia.

17 r some types of infection, in particular for ventilator-associated pneumonia.

18 the lowest concordance observed in cases of ventilator-associated pneumonia.

19 tive incidence of bloodstream infections and ventilator-associated pneumonia.

20 l care to evaluate its potential to decrease ventilator-associated pneumonia.

21 ve surveillance methods for the diagnosis of ventilator-associated pneumonia.

22 . aureus coverage in patients with suspected ventilator-associated pneumonia.

23 l criteria for establishing the diagnosis of ventilator-associated pneumonia.

24 ssfully implement programs aimed at reducing ventilator-associated pneumonia.

25 ssociated with a propensity to posttraumatic ventilator-associated pneumonia.

26 ating objective surveillance definitions for ventilator-associated pneumonia.

27 velopment of methicillin-resistant S. aureus ventilator-associated pneumonia.

28 rveillance culture before the development of ventilator-associated pneumonia.

29 ccus aureus has emerged as a common cause of ventilator-associated pneumonia.

30 idated as effective markers for exclusion of ventilator-associated pneumonia.

31 rdship in patients with clinically suspected ventilator-associated pneumonia.

32 hat is associated with hospital-acquired and ventilator-associated pneumonia.

33 nt in vivo fitness cost in a murine model of ventilator-associated pneumonia.

34 use remains high in patients with suspected ventilator-associated pneumonia.

35 tilated for at least 48 h, and had suspected ventilator-associated pneumonia.

36 haled gas could give an earlier diagnosis of ventilator-associated pneumonia.

37 h shockable rhythm are at increased risk for ventilator-associated pneumonia.

38 umonia were confirmed, including 51 of early ventilator-associated pneumonia.

39 judication committee determined diagnoses of ventilator-associated pneumonia.

40 ilator-associated complication, and probable ventilator-associated pneumonia.

41 ubglottic secretions plays a pivotal role in ventilator-associated pneumonia.

42 underscoring its potential in the context of ventilator-associated pneumonia.

43 age as a way to predict their involvement in ventilator-associated pneumonia.

44 ith subglottic secretion drainage to prevent ventilator-associated pneumonia.

45 difficult-to-treat pathogens likely to cause ventilator-associated pneumonia.

46 ients with respiratory tract colonization or ventilator- associated pneumonia.

47 ve infections, such as hospital-acquired and ventilator-associated pneumonias.

48 catheter-related bloodstream infections and ventilator-associated pneumonias.

49 The prevalence (n ventilator-associated pneumonia/1,000 ventilation days)

50 mial infections (27.3% and 43.8%), including ventilator-associated pneumonia (14.5% and 27.6%).

51 ile (4.5% vs 1.7%), and incidence density of ventilator-associated pneumonia (2.4/1,000 patient-days

52 Rates of ventilator-associated pneumonia (20% vs. 21%, p=.94), vo

53 Overall, 519 (71%) patients had ventilator-associated pneumonia, 239 (33%) had Acute Phy

54 Among the 47 patients with ventilator-associated pneumonia, 25 (58.2%) experienced

55 ction were bloodstream infection (64.3%) and ventilator-associated pneumonia (35.7%).

56 served with respect to the incidence of late ventilator-associated pneumonia (4% and 5%, respectively

57 Among 587 patients with suspected ventilator-associated pneumonia, 40 (6.8%) were colonize

58 . 3.1 +/- 2.7 days, p < 0.001), and rates of ventilator-associated pneumonia (42.5% vs. 8.0%; p < 0.0

59 OR, 30.7 [95% CI, 19.3-49.2]), prevention of ventilator-associated pneumonia (52% vs 33%, respectivel

60 The most common infection type was ventilator-associated pneumonia (52%); 7% of patients we

61 ted urinary tract infection, 13 versus 8 for ventilator-associated pneumonia, 6 versus 3 for incision

62 iratory specimen Gram stain for diagnosis of ventilator-associated pneumonia, absence of bacteria on

63 Of these, 83 patients (4%) had ventilator-associated pneumonia according to the America

64 >/=6 and >/=14 days had greater reduction in ventilator-associated pneumonia acquisition and also had

65 role of improved diagnosis and prevention of ventilator-associated pneumonia also showed relevant res

66 ed with improved outcome in the treatment of ventilator-associated pneumonia although the level of ev

67 Two hundred eight patients had ventilator-associated pneumonia and 135 had nonventilato

68 7 (9.5%) had methicillin-resistant S. aureus ventilator-associated pneumonia and 54 (13.9%) had methi

69 or more than 48 hours, 7,735 were at risk of ventilator-associated pneumonia and 9,747 were at risk o

70 d administration of systemic antibiotics for ventilator-associated pneumonia and any other infection.

71 Ventilator-associated pneumonia and bleed are the variab

72 nd survival were the assumptions surrounding ventilator-associated pneumonia and bleed.

73 ing; the effect of proton pump inhibitors on ventilator-associated pneumonia and C. difficile remain

74 t Staphylococcus aureus is a common cause of ventilator-associated pneumonia and can be identified by

75 Ventilator-associated pneumonia and catheter-related blo

76 Mean rates of ventilator-associated pneumonia and catheter-related blo

77 unit and hospital length of stay, rates for ventilator-associated pneumonia and central venous acces

78 length of stay and lowered the prevalence of ventilator-associated pneumonia and central venous acces

79 The impact was similar for ventilator-associated pneumonia and ICU-hospital-acquire

80 Ventilator-associated pneumonia and ICU-hospital-acquire

81 on cause of infection in cystic fibrosis and ventilator-associated pneumonia and in burn and wound pa

82 aureus as an etiology in most patients with ventilator-associated pneumonia and may decrease the nee

83 to reduce infectious complications including ventilator-associated pneumonia and may influence intens

84 ely ill population with clinically suspected ventilator-associated pneumonia and negative quantitativ

85 considered, as well as when stratified into ventilator-associated pneumonia and nonventilator ICU-ac

86 accurately predicted patients that developed ventilator-associated pneumonia and should now be tested

87 Use of aerosolised antibiotics for ventilator-associated pneumonia and ventilator-associate

88 Effective (aerosolized antibiotics for ventilator-associated pneumonia) and ineffective (procal

89 ship between ventilator-associated event and ventilator-associated pneumonia, and 3) the impact of ve

90 ly significant stress-related mucosal bleed, ventilator-associated pneumonia, and Clostridium diffici

91 fied acute physiology score II, diagnosis of ventilator-associated pneumonia, and infection by multid

92 nit (ICU) most commonly manifests as sepsis, ventilator-associated pneumonia, and infection of surgic

93 catheter-associated bloodstream infections, ventilator-associated pneumonia, and other healthcare-as

94 ement initiatives aimed at the prevention of ventilator-associated pneumonia, and other ventilator-as

95 redictor for methicillin-resistant S. aureus ventilator-associated pneumonia are 70.3% (95% confidenc

96 Septicemia and ventilator-associated pneumonia are two of the more seve

97 infections, including hospital-acquired and ventilator-associated pneumonia, are common in hospitali

98 ke surveillance of events possibly linked to ventilator-associated pneumonia as objective as possible

99 standardized vignettes of possible cases of ventilator-associated pneumonia as pneumonia or no pneum

100 e of the bacterial pathogens associated with ventilator-associated pneumonia, as well as with other n

101 rend shows a 55.83% reduction in the rate of ventilator-associated pneumonia at the end of the study

102 echanical ventilation, such as pneumothorax, ventilator-associated pneumonia, atelectasis, and pleura

103 oalveolar lavage to allow rapid diagnosis of ventilator associated pneumonia attributable to methicil

104 ventilator-associated pneumonia did not have ventilator-associated pneumonia because radiographic cri

105 ntibiotics for more than 5 days for treating ventilator-associated pneumonia before the occurrence of

106 the 133 eligible participants, 24 (18%) had ventilator-associated pneumonia by 2008 Pediatric criter

107 Although 20 participants were diagnosed with ventilator-associated pneumonia by 2008 Pediatric criter

108 conducted active prospective surveillance of ventilator-associated pneumonia by applying the definiti

109 significantly associated with P. aeruginosa ventilator-associated pneumonia by multivariate logistic

110 ion constructs detected less than a third of ventilator-associated pneumonia cases with a sensitivity

111 ver the study period, 20 patients (3.4%) had ventilator-associated pneumonia caused by extended-spect

112 f a COVID-19 patient who developed recurring ventilator-associated pneumonia caused by Pseudomonas ae

113 atients with nosocomial pneumonia (including ventilator-associated pneumonia) caused by Gram-negative

114 The pooled incidence density of ventilator-associated pneumonia, central line-associated

115 icularly damaging or fatal for patients with ventilator-associated pneumonia, chronic obstructive pul

116 atients with nosocomial pneumonia, including ventilator-associated pneumonia, compared with meropenem

117 Hospitalized patients with hospital-acquired/ventilator-associated pneumonia, complicated intraabdomi

118 enced-based interventions reduce the risk of ventilator-associated pneumonia, controversy has surroun

119 s Centers for Disease Control and Prevention ventilator-associated pneumonia criteria and physician d

120 Ventilator-associated pneumonia criteria applied in real

121 y fewer and different patients than previous ventilator-associated pneumonia criteria or physician di

122 During the study period, ventilator-associated pneumonia decreased from 2.50 to 1

123 sive care unit-related complications such as ventilator-associated pneumonia, deep vein thrombosis, a

124 all p<0.03); and had no change in mortality, ventilator-associated pneumonia, deep vein thrombosis, d

125 ructs failed to detect many patients who had ventilator-associated pneumonia, detected many cases tha

126 Ventilator-associated pneumonia developed in 20.4% of pa

127 Ventilator-associated pneumonia developed in 66.67%, 85.

128 secretion drainage is associated with fewer ventilator-associated pneumonia diagnoses, but it is unc

129 Ventilator-associated pneumonia diagnosis remains a deba

130 with National Health Safety Network probable ventilator-associated pneumonia did not have ventilator-

131 In this multicenter cohort study, ventilator-associated pneumonia did not occur more frequ

132 e prophylaxis in the context of experimental ventilator-associated pneumonia due to methicillin-resis

133 travenous phage therapy for the treatment of ventilator-associated pneumonia due to methicillin-resis

134 inical outcomes (ICU and hospital mortality, ventilator-associated pneumonia, duration of mechanical

135 The primary outcome was early ventilator-associated pneumonia (during the first 7 days

136 Infections (especially ventilator-associated pneumonia) during extracorporeal m

137 nd in vivo efficacy against strain 536 and a ventilator-associated pneumonia E. coli were tested.

138 We identified 32 ventilator-associated pneumonia, eight urinary tract inf

139 Adults with nosocomial pneumonia (including ventilator-associated pneumonia), enrolled at 136 centre

140 ntral line-associated bloodstream infection, ventilator-associated pneumonia/events, postprocedure pn

141 The frequency of ventilator-associated pneumonia fell from 8.1% to 1.3% (

142 prospectively and independently screened for ventilator-associated pneumonia from January 2009 to Jan

143 Secondary outcomes included incidence of ventilator-associated pneumonia, gastrointestinal hemorr

144 easure was aggregate concordance with the 14 ventilator-associated pneumonia guideline recommendation

145 A 2-yr multifaceted intervention to enhance ventilator-associated pneumonia guideline uptake was ass

146 s, as strategies to implement evidence-based ventilator-associated pneumonia guidelines on guideline

147 zed invasive techniques for the diagnosis of ventilator-associated pneumonia had lower rates of prolo

148 inhibitor use with Clostridium difficile and ventilator-associated pneumonia have raised concerns rec

149 When adjusted on prognostic variables, ventilator-associated pneumonia (hazard ratio, 1.38 (1.2

150 imbursement for patients with development of ventilator-associated pneumonia, hospitals need to devel

151 < 10), including pneumothorax, atelectasis, ventilator-associated pneumonia, hypoglycemia, hyperglyc

152 Condition criteria, and physician-diagnosed ventilator-associated pneumonia in a cohort of PICU pati

153 tive cohort study of patients with suspected ventilator-associated pneumonia in a medical ICU was con

154 Network in 2013, replacing surveillance for ventilator-associated pneumonia in adult inpatient locat

155 We investigated the epidemiology of ventilator-associated pneumonia in elderly ICU patients.

156 Ventilator-associated pneumonia in elderly patients was

157 nd oral care with povidone-iodine to prevent ventilator-associated pneumonia in high-risk patients.

158 cinetobacter baumannii is a leading cause of ventilator-associated pneumonia in intensive care units,

159 volvement of such pathogens in patients with ventilator-associated pneumonia in low-prevalence area.

160 atients with A. baumannii complex infection, ventilator-associated pneumonia in particular, the selec

161 ultidimensional approach on the reduction of ventilator-associated pneumonia in patients hospitalized

162 Oral care may decrease ventilator-associated pneumonia in the ICU.

163 period, there was a significant reduction in ventilator-associated pneumonia in the postintervention

164 thm for antibiotic discontinuation rules out ventilator-associated pneumonia in the setting of negati

165 Cultures were positive in 88% of ventilator-associated pneumonias in the American College

166 ons (incidence-rate ratio, 1.03; P=0.08), or ventilator-associated pneumonia (incidence-rate ratio, 0

167 catheter-associated urinary tract infection, ventilator-associated pneumonia, incisional surgical sit

168 d when investigating patients with suspected ventilator-associated pneumonia, including patient group

169 Ventilator-associated pneumonia is a difficult diagnosis

170 Ventilator-associated pneumonia is an important cause of

171 Ventilator-associated pneumonia is associated with incre

172 has recently proposed a major change in how ventilator-associated pneumonia is defined.

173 esentative study of hospitals, assignment of ventilator-associated pneumonia is extremely variable, e

174 Ventilator-associated pneumonia is frequent in ICUs.

175 Ventilator-associated pneumonia is one of the most commo

176 Ventilator-associated pneumonia is the most common inten

177 Ventilator-associated pneumonia is the most common inten

178 Ventilator-associated pneumonia is the most important in

179 the prevention, diagnosis, and treatment of ventilator-associated pneumonia may improve outcomes, bu

180 pergillus infection in adults with suspected ventilator-associated pneumonia.Methods: Two prospective

181 onal Nosocomial Infection Control Consortium ventilator-associated pneumonia multidimensional approac

182 ured trauma patients that went on to develop ventilator-associated pneumonia (n=10) was compared to t

183 g hospitals about classification of cases as ventilator-associated pneumonia/not ventilator-associate

184 Ventilator-associated pneumonia occurred in 103 middle-a

185 ing ventilation, microbiologically confirmed ventilator-associated pneumonia occurred in 15 patients

186 Ventilator-associated pneumonia occurred in 24 patients

187 -proven aspiration pneumonia and early-onset ventilator-associated pneumonia occurred in 54 patients

188 ilator-associated complication episodes, and ventilator-associated pneumonia occurrence: R = 0.69 and

189 nd ability to prevent Pseudomonas aeruginosa ventilator-associated pneumonia of KB001, a recombinant,

190 Regarding clinical signs and symptoms at ventilator-associated pneumonia onset, new temperature r

191 easures are poorly correlated with decreased ventilator-associated pneumonia or catheter-related bloo

192 ation in the 2 days before the occurrence of ventilator-associated pneumonia or ICU-hospital-acquired

193 The first three episodes of ventilator-associated pneumonia or ICU-hospital-acquired

194 ssociated condition cases (93%) did not have ventilator-associated pneumonia or other hospital-acquir

195 and in high-risk complex infections such as ventilator-associated pneumonia or sepsis where coloniza

196 lation, and had nosocomial pneumonia (either ventilator-associated pneumonia or ventilated hospital-a

197 omplications (1.6% vs 13%, respectively, for ventilator-associated pneumonia [OR, 0.15; 95% CI, 0.09-

198 ing did not significantly reduce the risk of ventilator-associated pneumonia overall.

199 to attenuate the effect of toothbrushing on ventilator-associated pneumonia (p for the interaction =

200 ity in empirically treated, culture-negative ventilator-associated pneumonia patients whose antibioti

201 ults showed that early mobilization improved ventilator-associated pneumonia patients' Medical Resear

202 served in one trial reporting fewer cases of ventilator-associated pneumonia per 1,000 ventilator day

203 d complexity of surveillance definitions for ventilator-associated pneumonia preclude meaningful inte

204 effect of subglottic secretion suctioning on ventilator-associated pneumonia prevalence and to assess

205 Ventilator-associated pneumonia prevalence as defined by

206 oning resulted in a significant reduction of ventilator-associated pneumonia prevalence associated wi

207 Corresponding P. aeruginosa ventilator-associated pneumonia prevalences were 4.1%, 3

208 Implementation of a ventilator-associated pneumonia prevention bundle was as

209 A four-element ventilator-associated pneumonia prevention bundle, consi

210 Existing ventilator-associated pneumonia prevention bundles are u

211 ch had not been achieved with earlier ad hoc ventilator-associated pneumonia prevention guidelines in

212 sociated with a significant reduction in the ventilator-associated pneumonia rate in the adult intens

213 Ventilator-associated pneumonia rate per 100 ventilator

214 at the end of the study period; that is, the ventilator-associated pneumonia rate was 55.83% lower th

215 secretion drainage was associated with lower ventilator-associated pneumonia rates (risk ratio, 0.58;

216 four trials, there was a trend toward lower ventilator-associated pneumonia rates (risk ratio, 0.77;

217 manual toothbrushing showed no difference in ventilator-associated pneumonia rates (risk ratio, 0.96;

218 secretion drainage is associated with lower ventilator-associated pneumonia rates but does not clear

219 Over the study period, ventilator-associated pneumonia rates decreased (events/

220 iated complication and possible and probable ventilator-associated pneumonia rates decreased from 3.1

221 The ventilator-associated pneumonia rates obtained in phase

222 In terms of ventilatory days, ventilator-associated pneumonia rates were 9.6 of 1,000

223 ventilator-associated pneumonia were pooled, ventilator-associated pneumonia rates were also signific

224 onia guidelines on guideline concordance and ventilator-associated pneumonia rates.

225 in guideline concordance and a reduction in ventilator-associated pneumonia rates.

226 nce; 4) process surveillance; 5) feedback of ventilator-associated pneumonia rates; and 6) performanc

227 sing nutritional support was associated with ventilator-associated pneumonia (relative risk, 1.19; 95

228 Our findings suggest that ventilator-associated pneumonia remains a common ICU inf

229 rgillus infection in patients with suspected ventilator-associated pneumonia remains uncharacterized

230 cheostomy presented less risk difference for ventilator-associated pneumonia (risk difference, 0.78;

231 ted that toothbrushing significantly reduced ventilator-associated pneumonia (risk ratio, 0.26; 95% c

232 The use of evidence-based bundles targeting ventilator-associated pneumonia seems to be a reasonable

233 xhaled gas were compared and correlated with ventilator-associated pneumonia severity.

234 n mobility spectrometry is able to detect 1) ventilator-associated pneumonia specific changes and 2)

235 mobility spectrometry for early detection of ventilator-associated pneumonia specific volatile organi

236 e second group of mice was infected with the ventilator-associated pneumonia strain and received 536_

237 adaptation of this bacteriophage toward the ventilator-associated pneumonia strain led to isolate a

238 The majority of mice infected by the ventilator-associated pneumonia strain were not rescued

239 tion surveillance did not perform as well as ventilator-associated pneumonia surveillance and had sev

240 Individuals responsible for ventilator-associated pneumonia surveillance at 43 U.S.

241 hythm resulted in a lower incidence of early ventilator-associated pneumonia than placebo.

242 ng limitations of the national definition of ventilator-associated pneumonia that was in place until

243 ontrol and Prevention Pediatric criteria for ventilator-associated pneumonia, the 2013 Adult Ventilat

244 ilation, moving from the current standard of ventilator-associated pneumonia to broader complications

245 ntral line-associated bloodstream infection, ventilator-associated pneumonia, urinary tract infection

246 more stringent criteria for surveillance of ventilator-associated pneumonia, use of the administrati

247 Ventilator-associated pneumonia (VAP) carries significan

248 patients started on antibiotics for possible ventilator-associated pneumonia (VAP) do not have pneumo

249 ual gastric volume is recommended to prevent ventilator-associated pneumonia (VAP) in patients receiv

250 lized forms of colistin for the treatment of ventilator-associated pneumonia (VAP) in patients withou

251 Ventilator-associated pneumonia (VAP) is a common health

252 Ventilator-associated pneumonia (VAP) is a common nosoco

253 Ventilator-associated pneumonia (VAP) is a leading cause

254 Rapid and accurate diagnosis of ventilator-associated pneumonia (VAP) is a major challen

255 Ventilator-associated pneumonia (VAP) is among the most

256 Accurate surveillance of ventilator-associated pneumonia (VAP) is hampered by sub

257 Diagnosis of ventilator-associated pneumonia (VAP) is imprecise.

258 The occurrence of ventilator-associated pneumonia (VAP) is linked to the a

259 Ventilator-associated pneumonia (VAP) is notoriously dif

260 Ventilator-associated pneumonia (VAP) is the commonest h

261 Ventilator-associated pneumonia (VAP) is the most common

262 The complexity and subjectivity of ventilator-associated pneumonia (VAP) surveillance limit

263 lly over a 3-week period from a patient with ventilator-associated pneumonia (VAP) who received clind

264 acteria are considered the primary causes of ventilator-associated pneumonia (VAP), a severe hospital

265 ssociated urinary tract infections (CAUTIs), ventilator-associated pneumonia (VAP), and Clostridium d

266 Ventilator-associated pneumonia (VAP), bloodstream infec

267 sk for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), including special

268 lator-associated tracheobronchitis (VAT) and ventilator-associated pneumonia (VAP).

269 occus aureus (MRSA) is an important cause of ventilator-associated pneumonia (VAP).

270 lator-associated tracheobronchitis (VAT) and ventilator-associated pneumonia (VAP).

271 respiratory tract infections, most commonly ventilator-associated pneumonia (VAP; 88% [36/41]).

272 in the composition of exhaled gas we induced ventilator-associated pneumonia via endobronchial instil

273 The rate of ventilator-associated pneumonia was 22.0 per 1,000 mecha

274 rol Consortium multidimensional approach for ventilator-associated pneumonia was associated with a si

275 oalveolar lavage fluid from all patients and ventilator-associated pneumonia was confirmed by at leas

276 Ventilator-associated pneumonia was confirmed by histolo

277 of aerosolized colistin in the treatment of ventilator-associated pneumonia was evaluated.

278 Mortality among patients with ventilator-associated pneumonia was higher among elderly

279 g phase 2, the multidimensional approach for ventilator-associated pneumonia was implemented at each

280 Each patient with suspected ventilator-associated pneumonia was included in the coho

281 Incidence of ventilator-associated pneumonia was lower in mechanicall

282 The incidence of early ventilator-associated pneumonia was lower with antibioti

283 cases as ventilator-associated pneumonia/not ventilator-associated pneumonia was nearly random (Fleis

284 Ventilator-associated pneumonia was the most common type

285 lidated cutoff, clinicians were advised that ventilator-associated pneumonia was unlikely and to cons

286 Using a rabbit model of ventilator-associated pneumonia we determined if gas chr

287 Sensitivity and specificity of diagnosing ventilator-associated pneumonia were 0.92 and 0.28 for v

288 The corresponding rates of ventilator-associated pneumonia were 8.5 vs. 1.2 cases p

289 -producing Enterobacteriaceae involvement in ventilator-associated pneumonia were 85.0% and 95.7%, re

290 hat both ICU-hospital-acquired pneumonia and ventilator-associated pneumonia were associated with an

291 After adjudication, 60 cases of ventilator-associated pneumonia were confirmed, includin

292 Other risk factors for mortality in ventilator-associated pneumonia were diabetes mellitus,

293 The odds of developing P. aeruginosa ventilator-associated pneumonia were eight times higher

294 the prevention, diagnosis, and treatment of ventilator-associated pneumonia were implemented using a

295 When data from the seven trials reporting ventilator-associated pneumonia were pooled, ventilator-

296 s study was to compare the observed rates of ventilator-associated pneumonia when using the National

297 ise was less common in elderly patients with ventilator-associated pneumonia, whereas more episodes a

298 eter-associated urinary tract infection, and ventilator-associated pneumonia), which have traditional

299 ith a statistically significant reduction in ventilator-associated pneumonia, which had not been achi

300 Of 50 patients with P. aeruginosa ventilator-associated pneumonia who underwent surveillan